Protagonist Therapeutics Inc. (NASDAQ:PTGX) changes shares on Friday trading session, with a change of -1.59% or -$0.3 shares. The trading starts at $18.77 and closed at $18.84 throughout the day. The trading session low price was $17.92 and day high was $18.79 on Friday, June 26. After the session, the Healthcare sector daily volume shifted to 1.3 million while its average volume is 1.04M. In other hand, the PTGX market cap reached to $649.09M.
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 6.31% and up 12.09% for month. Its quarterly performance was 188.79% above, while its half year performance is up 154.67%. PTGX yearly performance stood at positive 54.76% and rise 162.98% for year-to-date. Current recommendation for Protagonist Therapeutics Inc. is 1.60.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. PTGX EPS (TTM) for 12-month is -3.15. EPS for this year is -71.30%, while for the next year its value is -2.12. Its EPS Q/Q reached -24.90%. It has an EPS of -31.30% down for past five years.
FMR, LLC, RTW Investments LP and Johnson & Johnson Innovation – JJDC, Inc. are the top three holders in Protagonist Therapeutics Inc. (PTGX) stock. On Mar 30, 2020, FMR, LLC has 4.09 million shares which valued 28.9 million. On Mar 30, 2020, RTW Investments LP owned 2.66 million shares which valued at 18.78 million. On Mar 30, 2020, Johnson & Johnson Innovation – JJDC, Inc. has a total of 2.45 million shares which valued at 17.29 million. In the end, Johnson & Johnson Innovation – JJDC, Inc. have 8.93% shares outstanding of Protagonist Therapeutics Inc. (PTGX) on Mar 30, 2020. The insider ownership moved to 1.30% and institutional holding shifted to 78.00%.
The company posted an EPS (TTM) of -3.15. According to the most recent quarter report on (Jun 2020), 4 analysts estimated an average EPS of -0.66, while -1.18 EPS posted a year ago period. Analyst Estimated EPS for PTGX published in the report was -0.89–0.56 during the same period. Comparing with last year, the average estimated EPS was -1.18 which is lower than -0.72 which was posted for recent quarter EPS.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for PTGX rise 82.34% for period of 200 days. SMA for 50 days was 38.33% which is showing green signal, while SMA-20 was 11.28%. The moving average value for Protagonist Therapeutics Inc. (PTGX) is 9.63 and 16.43 for 200 and 50 days respectively.
Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in PTGX stock. On Mar 12, SELICK HAROLD E, Director, bought 12,000 trading shares at the cost of $6.70, which valued at 80400.0. On Dec 03, Giraudo Bryan, Director, bought 8,000 shares at the cost of $5.70, with total shares of 8,000. On Dec 03, Gupta Suneel, EVP Clinical Operations, bought 30,000 shares at the cost of 5.13. After this transaction, Gupta Suneel total shares reached to 49,500 which valued at 0.15 million.